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Norsk sammendrag 
Automatisert blod glukose kontroll – utvikling og uttesting av en kunstig endokrin 
pankreas bestående av en intravaskulær glukose monitor og en ny tilnærming til 
insulin farmakologi 
Denne PhD-avhandlingen omhandler utviklingen og testingen av en ny kunstig endokrin 
pankreas. Bestanddelene i en kunstig endokrin pankreas er en glukose-sensor, en insulin 
infusjons sprøyte og en kontroll-algoritme. Vårt utgangspunkt var at eksisterende 
tilnærminger til denne problemstillingen ikke fungerer, og vi identifiserte noen av de 
bakenforliggende biologiske forklaringene til hvorfor så er tilfelle. Vi satte så ned en 
rekke forskningsspørsmål/-problemstillinger med det endelige og overordene mål å lage 
en fungerende kunstig endokrin pankreas. 
 
Den første artikkelen beskriver utprøvingen av en ny intravaskulær glukose-sensor – 
IvS-1 – i en levende grise-modell. Studiet viste at verdier målt med IvS-1 hadde god 
overensstemmelse med glukose-verdier fra samtidige blodprøver, og at respons-tiden i 
apparatet var rask. Den andre artikkelen studerte farmakologiske egenskaper ved 
intravenøs administrering av insulin. Hovedfokus var å finne tids-forskyvningen fra gitt 
insulin til endringer i grisenes blod glukose nivå. Den tredje artikkelen viste at blod 
glukose verdien var den samme i arterielt og venøst blod, selv under særdeles ustabile 
sirkulatoriske forhold. I den fjerde artikkelen satte vi sammen all vår akkumulerte 
kunnskap og laget en kunstig endokrin pankreas. Vi brukte IvS-1 som glukose-sensor 
og regulerte ned blod glukosenivået i diabetiske griser vha. vår nyutviklete insulin-
algoritme med repeterte intravenøse insulin bolus. 
 
Avhandlingen konkluderes med å besvare forskningsspørsmålene, og slår fast at en 
kunstig endokrin pankreas er biologisk mulig. Men det vil være særdeles teknisk 
krevende å lage et stabilt system som kan fungere i en klinisk setting..
Cand.med  Nils Kristian Skjærvold 
Institutt for Sirkulasjon og bildediagnostikk, NTNU 
Hovedveileder: Professor Petter Aadahl 
Biveiledere: Professor Dag Roar Hjelme og professor Olav Spigset 
Ovennevnte avhandling er funnet verdig til å forsvares offentlig
for graden PhD i klinisk medisin 
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Summary
This thesis describes the stepwise development and testing of the components of a novel 
artificial endocrine pancreas, consisting of a continuous glucose monitor, an insulin 
infusion device and a control algorithm. The starting point was the belief that current 
approaches to the challenges posed by creating an artificial endocrine pancreas do not 
work, and we identified some of the biological mechanisms that can explain this lack of 
success. We further established a set of research questions with the overall goal of 
constructing a working artificial endocrine pancreas. 
The first paper describes the in vivo (pig model) testing of a prototype of a new 
intravascular continuous glucose monitor, the IvS-1. The study determined that the 
monitor was able to produce readings with a reasonably fast response time that highly 
agreed with simultaneously drawn blood samples. The second study examined the 
pharmacological properties of intravenous insulin boluses, and estimated the time 
delays from insulin administration until changes in the blood glucose level. The third 
study demonstrated that blood glucose levels were the same in the arterial and venous 
systems, even at times of great circulatory stress. The fourth study relied on our 
accumulated knowledge to enable us to construct an artificial endocrine pancreas using 
the IvS-1 and a novel insulin regulatory algorithm based on insulin boluses. We then 
regulated the blood glucose level in diabetic pigs in a proof-of-concept study. 
The thesis concludes by answering the research questions, and asserts that the 
construction of an artificial endocrine pancreas is possible from a biological standpoint. 
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However, there are several serious technological challenges that have to be overcome in 
order to make a stable system for in-hospital – and later outpatient – use.  
 13
Introduction
Hyperglycemia
Diabetes mellitus is a highly prevalent disease worldwide. According to the World 
Health Organization, diabetes affected approximately 346 million people in 2011, 
caused an estimated 3.4 million deaths in 2004, and is often described as an epidemic 
(1). Type 1 diabetes is a condition where pancreatic beta cells are destroyed as a result 
of mechanisms that are not fully understood. The illness usually has its debut in 
childhood, and renders the patient absolutely dependent on insulin. Type 2 diabetes is 
considered a “lifestyle” disease, although much evidence points to a genetic disposition. 
The illness probably combines increased insulin resistance (in liver, muscles and fat) 
with decreased insulin production. In addition to classical type 1 and type 2 diabetes, 
there are several clinical syndromes of dysglycemia such as: mature onset diabetes of 
the young (MODY), late-onset type 1 diabetes, gestational diabetes, etc. (2). 
Critically ill patients in intensive care units (ICU) of modern hospitals tend to develop 
hyperglycemia as a result of a series of mechanisms involving general organ 
dysfunction, their catabolic state and iatrogenic factors such as steroid therapy and high 
doses of dietary sugars (3,4). At the turn of the millennium, several studies showed 
beneficial outcomes in ICU patients – a shorter ICU stay, fewer complications and 
lower mortality – if their blood glucose levels (BGL) were kept within normal values 
(4.5 – 6.0 mmol/l) with the use of insulin infusions (5-7). However, subsequent studies 
have failed to replicate these promising findings (8,9). This has led to what could be 
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called a blood glucose controversy, where different research groups are fighting over 
the pros and cons of tight glycemic control. 
Glucose/insulin (patho-) physiology 
The insulin/glucose regulatory system is complex and not fully understood. Insulin is 
secreted from the beta cells of the pancreas into the portal blood stream. During a 
sudden increase in BGLs there will be a biphasic increase in plasma insulin 
concentration; an initial rapid surge with a peak concentration within minutes is caused 
by the release of stored insulin from granules, while a second steadily continuing 
increase is caused by the instant secretion of newly synthetized insulin (2). However, 
studies dating back as far as the 1920s have shown that BGLs in resting mammalians 
are not stable, but display tiny oscillations with a periodicity of 10 – 15 minutes (10-13). 
Recent research has attributed this to the pulsatile nature of pancreatic beta cells 
(14,15). Insulin is released into the portal blood stream in synchronized bursts with a 
periodicity of approximately five minutes (16-19). The amount of insulin released with 
each burst is adjusted in conjunction with the existing BGL and the direction of change 
of the BGL at that time (20). Even in periods with a stable demand and supply of 
glucose, insulin pulses are always changing, resulting in small variations in BGLs 
(16,19).  
Glucagon is the system’s main counter-regulatory hormone and has an effect that is 
opposite that of insulin. Interestingly, glucagon is released from the pancreas anti-
synchronally with insulin, and with the same periodicity (21,22). 
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The pulsatility of pancreatic beta cells and hence the oscillatory insulin levels seem to 
diminish in type 2 diabetes (23,24). Plasma insulin or BGL oscillations in ICU patients 
have not been studied. However, a recent study found gross decomplexification in the 
variation in BGL time series in ICU non-survivors (25). This indicates a vital failure in 
their insulin/glucose regulatory system, meaning that their hyperglycemia is not merely 
caused by glucose overload. 
Blood glucose control and blood glucose measurement 
The traditional methods for BGL control in diabetic patients are dietary regulation, 
subcutaneous injections of insulin, and/or (in type 2 diabetes) oral medications 
(biguanides, sulfonylurea derivatives, and others) (26).  
Insulin was first isolated in 1922, and very soon afterwards was used in the treatment of 
diabetes mellitus, which resulted in a dramatic improvement in the lives of diabetic 
patients (27). In the first decades after WW II, the focus was to prolong the acting time 
of insulin to limit the number of injections, leading to the first “intermediate-acting” 
families of insulin in the 1940s and 1950s, and “long-acting” families starting in the 
1980s (28). In recent years, “short-” and “ultra-short acting” insulin have been produced 
to meet the needs of current multiple daily insulin injection regimes and insulin pump 
therapy (29). Earlier forms of insulin were extracted from bovine and porcine pancreas, 
while most current insulin for medical use is produced with modern recombinant 
techniques. Most recently, subcutaneous insulin pumps have emerged for diabetic 
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control in type 1 diabetes patients, gaining widespread popularity in the USA and in 
northern Europe (30).  
Intravenous insulin infusion, on the other hand, is used only in hospitals for control in 
complicated diabetes (such as in diabetic ketoacidosis) and in glycemic control in ICU 
patients (31). It is generally accepted that intravenous insulin administration yields the 
fastest onset, but there are very few studies that examine the pharmacology of 
intravenous insulin administration. The elimination half-life of insulin is reported to be 
approximately 6 minutes (32). This means that by using an ordinary “rule of thumb,” it 
will take approximately 30 minutes for an intravenous insulin infusion to reach steady-
state plasma levels (5 times its elimination half-life). However, there is probably an 
unknown time delay in the pharmacodynamic action of insulin, meaning that the time 
from a change in the stable plasma values of insulin until a concurrent change in BGL is 
not known. We have not found any studies that examine the time lags between changes 
in intravenous insulin administration and changes in BGL. 
The lives of diabetic patients have been very much improved since the introduction of 
lightweight easy-to-use blood glucose monitors for home use. These devices require a 
small blood specimen obtained by a lancet, and enable multiple daily insulin injection 
regimes and a more normalized diet (33). Over the last two decades, systems for 
continuous blood glucose measurement (CGM) have been developed. These instruments 
use an electrochemical sensing unit based on the same principle as the glucose oxidase 
sensors found in standard blood gas analyzers. Glucose is converted to gluconic acid 
and hydrogen peroxide, where the latter delivers electrons to the electrode and creates 
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an electric current proportional to the concentration of glucose. The sensing unit is 
located in a needle for minimally invasive subcutaneous positioning, and a box with the 
processing unit, power supply and output display is carried attached to the body (34-38).  
There has been some research activity on intravascular CGM as well. One study has 
described the feasibility of enzymatic sensors (essentially the same technology as a 
subcutaneous CGM) in dogs. The sensors were implanted in the central caval vein for 1 
– 15 weeks and demonstrated acceptable agreement with blood glucose values and high 
bio-compatibility (39). As recently as 2006, a study was published describing the use of 
an enzymatic intravascular CGM in combination with intra-peritoneal insulin delivery 
(40). However, a recent review from (among others) the same author suggests that both 
intravenous CGM as well as intra-peritoneal insulin delivery have been abandoned (41). 
However, today there appear to be several commercial groups working with 
intravascular CGM using various technological approaches. The motivation is probably 
the introduction of tight glycemic control in ICUs, where the invasive approach of 
intravascular positioning is more acceptable than in outpatient care. It is complicated to 
get a comprehensive overview of all of the developments this field, since these groups 
rarely publish their results in scientific journals, and there are few review articles. A 
recent report from the NTNU Technology Transfer Office identified and classified 11 
companies/products that were working on intravascular CGM (Table 1), none of which 
have yet reached the commercial market. 
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Classification Product (Company)  Technology 
Intravascular GlySure Fluorescence and fiber 
optic sensor 
GluCath (Glumetrics) Fluorescence and fiber 
optic sensor 
iGlyko Fluorescence and fiber 
optic sensor 
Glucoclear (DexCom & 
Edwards Lifescience)  
Electrochemical sensor 
inside an IV catheter 
Intravascular microdialysis Eirus CGM (Dipylon 
Medical) 
Microdialysis 
MicroEye (Probe 
Scientific)  
Microdialysis 
Periodic blood samples Proxima (Sphere Medical) Microchip 
Cascade Metrix Electrochemical 
OptiScanner (Optiscan 
Biomedical) 
IR spectroscopy 
GlucoScout (Via Medical)  Electrochemical 
STG-22 (Nikkiso)  Electrochemical 
 
Table 1: Overview of different commercial approaches to intravascular continuous 
glucose measurement (supplied by and with permission from Nicolas Elvemo at NTNU 
Technology Transfer Office) 
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Artificial endocrine pancreas (AEP) 
The ultimate solution to BGL regulation in diabetic patients is generally seen as the 
artificial endocrine pancreas (AEP). It consists of a CGM, an insulin infusion system 
and a control algorithm, assembled as a fully automated closed loop regulation system 
with no need for manual adjustment (41-47) .  
In the late 1950s, Technicon Instruments developed the Autoanalyzer, which was 
capable of online continuous measurements of glucose in whole blood. This instrument 
was the ancestor of a series of experiments that used similar techniques: Blood was 
withdrawn from a dual-lumen intravenous catheter and continuously analyzed ex vivo, 
usually using the glucose-oxidase method (48). The time from when blood was drawn 
until the output reading was available was approximately five minutes. This type of 
system could be used both as a diagnostic tool in the management of diabetic patients 
(49), and as helpful guidance during surgical resection of insulinomas (50). These 
instruments were used as the input link in the first generation AEPs, which were 
extensively studied during the 1970s, and which led to the development of the Biostator 
(51) and later the STG-22 (52-55). In these systems, insulin is infused into the patient 
through an intravenous cannula, and the insulin infusion rate is regulated by a simple 
algorithm. These systems are able to regulate blood glucose levels quite well. However, 
they are hampered by their large size, their invasiveness and the need to immobilize the 
patient, making them suitable only for monitoring during surgery, intensive care and 
possibly as research tools. 
 Figur
Durin
been
subcu
clear
stand
been
day, 
62).  
A ser
tradit
class
mode
in BG
e 1: Outlin
g the past 
 focused on
taneous in
ly have som
ard compo
 tested in cl
and always
ious challe
ional meth
ical proport
l the insuli
L, the curr
e of an artif
decade, mo
 combining
sulin pump
e advantag
nents, whic
inical trials
 with a man
nge to the c
od used by 
ional-integ
n/glucose s
ent BGL an
icial endoc
st of the res
 the use of 
s (43,44). T
es as a resu
h should yi
, but few ha
ual backup
onstruction
the early B
ral-derivate
ystem at all
d its direct
rine pancre
earch on A
off-the-she
hese system
lt of their m
eld relative
ve been tes
 system to 
 of an AEP
iostator and
 (PID) cont
, but merel
ion of chan
as. 
EP in Euro
lf subcutane
s are desig
inimal inv
ly low cost
ted for mo
avoid unwa
 is the insu
 probably b
roller. PID
y address th
ge in order
pe and Nor
ous CGM 
ned for out
asiveness a
s. Several sy
re than a few
nted hypog
lin control a
y the STG-
 controllers
e accumula
 to calculate
 
th America
and 
patient use
nd use of 
stems hav
 hours to 
lycemia (56
lgorithm. T
22 is the 
 do not try 
ted past er
 the approp
20
 has 
 and 
e 
one 
-
he 
to 
rors 
riate 
 21
insulin dose (63-65). PID controllers have now been basically abandoned but are still 
used in a few AEP studies (62,66,67). 
The main problem posed by PID controllers is the serious time-delay issue, which 
affects all aspects of the AEP, from the time delay in BGL between the blood 
compartment and the subcutaneous tissue where the CGM is located to the time delay 
from subcutaneously administered insulin until a change in BGL (68-70). Several 
researchers have tried to mathematically model the natural glucose/insulin regulatory 
system, and the early “minimal model” by Bergman constitutes the foundation of most 
of these models (71). Adapting these models to a control algorithm results in what is 
called model-predictive-control (MPC) (72-75). Most research groups working on AEP 
use MPC, but a group led by Roman Hovorka at the University of Cambridge clearly 
has the lead. The current models are undoubtedly impressive, but using MPC in 
working AEP systems is subject to several limitations. First of all, as stated above, 
current AEP systems only work for a few hours. In a recent review, Hovorka 
downgrades expectations regarding the future of AEP, stating: 
“Nowadays, early generations of the artificial pancreas are setting less ambitious but 
realistic and clinically important goals to prevent hypoglycemia or to reduce its 
duration and severity whilst improving overall glucose control” (44) 
Other leading researchers are more optimistic regarding future subcutaneous-based 
AEP, stating: 
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“Finally, fully automated closed-loop is expected to deliver safe and efficacious glucose 
control at home for a prolonged period of time” (41) 
Our group doubts whether a fully automated AEP is possible using the subcutaneous 
route (given that technical issues such as long-term stability and bio-compatibility must 
be addressed), because we think there are inherent limitations in the overall approach. 
Some critical issues are: 1) insulin sensitivity in the natural insulin/glucose regulatory 
system, which is constantly changing (76) and constitutes a serious challenge in 
forecasting BGL values; 2) the oscillatory nature of resting BGL and the pulsatility of 
insulin secretion; 3) the possibility, suggested by some authors, that the insulin/glucose 
regulatory system exhibits deterministic chaotic components (77), meaning that 
arbitrary small changes in the initial condition cause large future errors so that it is not 
possible to foresee the effect of insulin over time, no matter how complicated the 
pharmacokinetic model is; 4) and finally, the roles of glucagon and other counter-
regulatory hormones are not included. 
This thesis takes a new look at the physiology of glucose control by in vivo testing a 
novel intravascular CGM and by re-investigating an intravenous mode of insulin 
administration. We propose a new approach to combining these aspects into a new AEP, 
concluding with in vivo test of the system.  
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Aims of the study 
The overall aim was to develop a possible technological and biological platform for 
future automated blood glucose regulation by the intravenous/intravenous route, and to 
test the feasibility of this system in an animal model. 
Aim 1: To test whether a novel intravascular continuous glucose monitor could measure 
blood glucose in good agreement with state-of-the-art blood sample analyses of glucose, 
and with a minimal time delay. To further develop the system to provide real-time 
readouts of the current blood glucose level. 
Aim 2: To determine the inherent lag time in the insulin/blood glucose system. To use 
this information to make a new algorithm for rapid and predictable blood glucose 
control.  
Aim 3: To get a firm idea of the pros and cons of glucose monitor positioning in 
different intravascular locations. 
Aim 4: To establish a diabetic pig model. 
Aim 5: To put all of this information together in the newly adapted glucose control 
algorithm and the intravascular continuous glucose monitor to regulate the blood 
glucose level in diabetic pigs.  
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Methodological considerations 
The IvS-1 CGM 
The IvS-1 sensor (Invivosense, Trondheim, Norway) is a biosensor with a hydrogel 
matrix incorporated with 3-phenylboronic acid. The gel contracts with rising glucose 
concentrations as a consequence of glucose-induced cross binding of the phenylboronic 
molecules. The hydrogel is fabricated on the tip of an optical fiber, and the whole sensor 
is covered with a partly heparinized semi-permeable coating.  The diameter of the gel is 
measured using an interferometric technique. Changes in glucose concentrations cause 
the volume of the gel to change, causing its diameter to change accordingly (78). The 
sensor only measures a relative change in glucose concentration, and needs to be 
calibrated against some other method of glucose measurement.  
In the original version (used in Paper I) the output unit and user interface of the IvS-1 
only displayed the continuous length measurement of the gel. The glucose values were 
calculated afterwards; the length measurement data had to be calibrated with 
simultaneously sampled blood sample glucose measurements (from a Radiometer ABL 
720 blood gas analyzer; Radiometer, Brønshøj, Denmark). Additionally, the data were 
corrected based on the pH measurements from the blood samples, and a linear drift 
constant was added to correct for the constant background swelling of the gel.   
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Figure 2: Pictures that show the hydrogel part of the IvS-1 continuous blood glucose 
monitor at increasing magnification. 
In order to use the IvS-1 data as part of the AEP trials in Paper IV, we needed the 
system to yield real-time BGL data. This was achieved by an in vitro calibration 
procedure where the sensors were exposed to three buffer solutions of 0.0, 2.0 and 10.0 
mmol/l glucose. After insertion and stabilization of the sensor, one-point calibration was 
achieved by adjusting the IvS-1 output in accordance with blood samples. This was very 
challenging when there were great oscillations in values; because the time from blood is 
withdrawn until the glucose value is obtained is approximately two minutes. By this 
time, the animals’ real BGL could have changed by several decimals mmol/l. The 
software for the sensor system (LabView application; National Instruments, Austin, TX) 
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therefore had to adjust the current output in accordance with the output at the time of 
blood withdrawal, which was not easily accomplished.  
The animal model 
Our group has a long tradition in the use of pigs in the laboratory. The advantages of 
pigs are their physiological similarity to humans; the size of the animal, including its 
organs and blood vessels are such that standard instruments and equipment used in 
humans can be used; and their ease of handling and relative inexpensiveness and easy 
availability (79). Handling, fasting, anesthesia, surgical preparation and the killing of 
the animals is described in the papers (the most complete details can be found in Paper 
I). 
In Study IV we had to construct a diabetic pig model, and we chose to do this using 
streptozotocin, which induces beta cell destruction. This is a well-known method, 
mostly used in rodents but also to some extent in swine (80-82). The available literature 
regarding streptozotocin-induced diabetes in swine is based on the construction of 
lasting diabetic models in mini-pigs. Our approach was a little different from those 
described previously, as we only wanted partly diabetic individuals and we only needed 
the animals for a short acute experiment. As the drug is very expensive, we had to find 
the smallest working dose with the correct time interval from drug introduction until the 
day of the experiment, while unable to afford to conduct any trials before the real 
experiment. That was indeed a challenging task, and resulted in the fact that not all 
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animals became as diabetic as we wanted. Nevertheless, the model was fair enough for 
use in this proof-of-concept study. 
All animal experiments were conducted in accordance with the European Convention 
for the Protection of Vertebrate Animals used for Experimental and Other Scientific 
Purposes (83) and were approved by the Norwegian State Commission for Animal 
Experimentation. In all animal experimentation the “three Rs” must be considered (84): 
Replacement: The studies reported in this thesis had to be performed on an intact 
organism, because we were seeking information about the complicated and not fully 
understood interplay of the insulin glucose regulatory system. In addition, the validation 
of the IvS-1 reported in Paper I warranted the use of an animal model.  
Reduction: We always analyzed the data continuously as the studies went on to reduce 
the workload, the cost and the use of animals, and I do not think that we performed any 
unnecessary animal sacrifices. One could ask whether the same animals could have 
been used several times. This is not so easy, both because of the animal welfare issues 
(multiple trials/anesthesia, postoperative care) as well as the fact that domestic pigs 
grow very fast. In the future, it might be more reasonable to create a long-time diabetic 
pig model by using some type of miniature pig, instrumenting them with permanent 
catheters and using only light sedation for multiple studies. 
Refinement: We believe that our general knowledge regarding pigs in the laboratory as 
well as our experience with human anesthesia made it possible to keep the animal 
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suffering at an absolute minimum. In addition, most of the experiments were acute 
experiments. We always strived to keep our techniques and measurements at the highest 
possible level to yield good and trustworthy results. 
Data handling and statistics 
 Paper I involved comparing the performance of the IvS-1 with standard blood gas 
analyses obtained from the Radiometer ABL 720 machine. Ordinary statistics, such as 
correlation and regression, are not very useful in assessing the performance of the 
ability of different medical technological instruments to measure the same physiological 
variable. This is so because there is no null hypothesis, the two sets of measurements 
should ideally to be the same (85-87). We therefore compared the measurements using a 
Bland-Altman analysis, calculating the mean bias and the 95 % limits of agreement. In 
addition, since the measurements were obtained from a set of probes in a set of pigs, 
they were not independent. We therefore performed analyses of variance as recently 
described by Bland and Altman to check for possible clustering at the animal and sensor 
level (88). A problem with the latter method is that it does not allow for adjusting for 
clustering at more than two levels (i.e. hierarchical measurements; here: pigs < probes < 
measurement). However, since we did not find any clustering of importance on any of 
the levels (we performed the analysis twice), we found the method to be sufficient. 
In Paper II we analyzed the effect of three different bolus doses of insulin on a series of 
pre-defined variables in four pigs: The time until the first detectable decrease in BGL 
(Tdecr), the maximum rate of decrease (MRD), the time until MRD (Tdecrmax), the 
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maximum decrease in BGL (ǻCmax), the time until the lowest measured BGL (Tmin) and 
the area corresponding to the drop in the BGL curve for the first 30 minutes after the 
insulin bolus administration (the integral of BGL30 – BGL0 =area over the curve from 0 
to 30 minutes; AOC0-30); see Figure 1, Paper II. To account for the clustering in animals 
we used linear mixed effect models with insulin dose as the fixed effect, the animal as 
the random effect and the defined variables as the outcome variables (89).  
In Paper III we made a point of showing the importance of treating clustered variables 
as non-independent. We compared arterial and mixed venous BGLs from a set of pigs 
from two different studies (study < pig < sample). We obtained a small mean difference 
between the measurements, and considered this difference using both the ordinary 
Student’s t-test and mixed effect models. 
In Paper IV we were able to use ordinary descriptive statistics. 
All the statistical analyses were conducted using R software, version 2.10.1 (the R 
Foundation for Statistical Computing, Vienna, Austria).  
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Summary of results (from papers) 
Paper I 
The aim of the study was to validate the performance of the IvS-1 in a pig model that 
involved the use of 20 different probes in seven animals (one to four probes in each 
animal), which resulted in 807 paired IvS-1/blood gas readings. Fluctuations in the BGL 
curve were achieved by intravenous insulin and glucose. The sensors were tested over a 
range of blood glucose values with the lowest value at 0.63 mmol/l and the highest at 
15.75 mmol/l. The mean bias between the measurements (IvS-1 – ABL) was 0.0131 
mmol/l with a standard deviation of 0.470 mmol/l and a 95 % limits of agreements of (- 
0.908, 0.934) mmol/l (Figure 1, Paper I). Among the 121 paired measurements in the 
hypoglycemic area below 2.2 mmol/l, the mean bias was – 0.0435 mmol/l with a 
standard deviation of 0.260 mmol/lol/l and a 95% limits of agreements of (– 0.553, 
0.466) mmol/l. 
Paper II 
The aim of the study was to predict the lag time in the insulin/blood glucose system, i.e. 
to find the time from intravenous insulin administration until predefined changes in the 
BGL were observed. We reported findings from studies in 12 pigs. We found that 
intravenous insulin infusions at “clinical” rates led the BGL to decline slowly. We 
therefore introduced intravenous bolus injections (IB) as an alternative, using three 
different insulin doses of 0.01, 0.02 and 0.04 IU/kg. IB led to a first detectable decrease 
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(Tdecr) in 2 – 6 minutes, a maximum rate of decrease (Tdecrmax) shortly thereafter, and a 
nadir value (Tmin) in 15 – 20 minutes before the BGL started to rise again. These time 
variables were independent of the IB dose. We found the maximum rate of decrease 
(MRD) to vary from 0.10 to 0.14 mmol/l/min dependent on the IB dose. The maximum 
decrease (ǻCmax) as well as the drop in the BGL curve for the first 30 minutes (AOC0-30) 
were also dependent on the IB dose. 
Paper III 
The aim of this study was to compare BGL values obtained from simultaneously drawn 
arterial and mixed venous blood samples in a pig model of gross circulatory stress. We 
used previously collected material from an ischemia/reperfusion model that consisted of 
116 paired data sets from 11 pigs in two studies. We found a mean difference between 
the BGL values of 0.065 mmol/l, with the mixed venous value slightly higher than the 
arterial value. However, when the values were compared using a mixed effect model 
where the experiments and the subjects were included as random effects, we found no 
difference between the groups. We concluded that BGL values obtained from the two 
locations were the same. 
Paper IV 
In this study we constructed an insulin bolus algorithm by using our knowledge from 
Paper II. We constructed a diabetic pig model, and reprogrammed the IvS-1 to be able 
to display real-time BGL values by introducing calibration procedures and automated 
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compensation for sensor drift. The aim was to adjust the BGL of the diabetic animals by 
lowering the BGL to target values (4.5 – 6.0 mmol/l) in one to two hours, and to keep 
their BGL within those values for the rest of the study period. The animals developed a 
mildly diabetic state from streptozotocin pre-treatment (starting BGL, BGL0 from 7.46 
to 14.06 mmol/l). They were steadily brought into the target range in 21 to 121 min, 
depending on their BGL0. The animals were then kept within the target for 128 to 238 
min; the time at hypoglycemic levels below 4.5 mmol/l varied from 2.9 to 51.1 min. 
The main problems were the drift of the IvS-1 sensor and difficulties with the 
calibration procedure, which led to incorrect real-time BGL values. The study 
confirmed our hypotheses regarding this new principle for blood glucose control, and 
the algorithm was constantly improved during the study to produce the best results in 
the last animals.   
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Results and discussion 
Validation of the IvS-1 CGM 
In Paper I we concluded that the performance of the IvS-1 was promising with 
measurements in high agreement with the Radiometer ABL 720 analyzer, and 
especially that the sensor performed well in the low glucose range. It should be noted 
that the much-used term accuracy is somewhat problematic, as this requires a 
comparison with a true value that cannot be obtained when it comes to physiological 
measurements such as BGL (85). At best, the agreement can be compared with the best 
available method (the gold standard). Nevertheless, the term accuracy is so frequently a 
part of any discussion of CGMs that I too will use it to some extent1. In the published 
article we stated that the variance was equally spread throughout the range of 
measurements (Figure 1, Paper I). However, it is surely possible to argue that the values 
in the highest range have somewhat higher variances. The reason for this is probably 
that we included paired data taken in the first few minutes after the glucose boluses, and 
as a consequence of the unstable physiology of the model at this time and the fact that 
                                                 
1 To complicate the issue further, it is possible to argue that when one instrument is calibrated with 
another, the first is defined as the “gold standard”, for which the term accuracy would be more suitable. 
This means that in Paper I, when the properties of the IvS-1 were tested, the word agreement should be 
used, while in Paper IV, when the IvS-1 was calibrated with the ABL 720, the word accuracy would be 
most correct. In addition to accuracy/agreement the concept of precision is important when it comes to 
examining the variations in quantitative laboratory data. If the same biochemical variable (e.g. glucose) is 
measured repeatedly from the same biological sample (e.g. blood) using the same laboratory instrument 
(e.g. IvS-1), there will be small differences. The magnitude of this variation is the precision of the 
instrument. In the future, the accuracy/agreement and the precision of the IvS-1 (the analytical variance) 
will have to be measured in order to create an AEP, because it is necessary to know when a change in 
BGL readings corresponds to a real change in the subject’s BGL and when it could be attributed to 
variance in the instrument.  
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the response time of the sensor is about two minutes (see next paragraph), these paired 
data would naturally have high variances. 
We did not originally aim to measure response time, as the fundamental importance of 
this parameter (especially in the development of the artificial pancreas) was not clear to 
us at the time of the study. The reviewers of the paper suggested we re-examine our 
material to look for opportunities to assess response time. We then were able to 
construct a figure (Figure 2, Paper I), showing that the IvS-1 readings followed the rise 
in BGL after an IV glucose bolus, and by the time of the next blood sample five minutes 
later, the sensor readings were already falling. Later, and especially in the work for 
Paper IV, we performed glucose bolus tests of the sensors to look specifically at 
response time (as well as the total response). These tests showed that when a large 
glucose bolus was given, the time from bolus until the sensor reached its maximum 
value was approximately 2 minutes (Figure 3).  
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Figure 3: Example of IV glucose bolus test of an IvS-1 sensor. It is reasonable to 
believe that the “true” BGL will reach its maximum value almost instantaneously at the 
time of bolus injection, followed by an immediate exponential decay. The maximum 
IvS-1 reading is 2 minutes after the bolus time, indicating a response time of 2 minutes. 
In Paper I some sensors broke down, which resulted in increased drifting and eventually 
failure. The sensors used were fabricated with different types of coating, although most 
of them were heparinized. We believe that bio-incompatibility, which caused clotting, 
triggered a chemical degradation mechanism in the sensor material. Another 
explanation for increased drift during clotting is that a biofilm on the sensor might 
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constitute some kind of microenvironment where the glucose content might be different 
than in the overall blood compartment (90). We also believe the intravenous positioning 
enhanced the clotting problem due to low pressures and flows. In subsequent 
experiments in Paper IV, we switched to peripheral intraarterial positioning only, using 
the femoral artery. In these experiments the bio-compatibility issue seemed to have 
almost vanished, although this remains to be confirmed in long-term experiments. Pigs 
do hyper-coagulate (79), and this was a problem especially in the early experiments. 
However, we found that the clotting tendencies of the animals were highly dependent 
upon surgical stress, and in Paper IV this was kept at an absolute minimum. 
Stability issues caused by measurement drifting independent of bio-incompatibility are 
also a problem, and constitute the biggest challenge both during the studies as well as in 
the future work with the sensor. The problem is caused by a slow background swelling 
of the hydrogel in most of the sensors. For the most part, this drifting seemed to be 
linear, and in Paper I (where the IvS-1 readings were interpreted in retrospect) we could 
adjust for the drift. Sometimes the drifting increased abruptly, which posed serious 
problems. We  interpreted this as a bio-compatibility/clotting problem and usually 
considered the actual sensor to be broken. The background swelling became a serious 
obstacle in the work with Paper IV when we were trying to get real-time BGL values 
from the IvS-1 and implement the artificial pancreas algorithm. It was very difficult to 
find the correct linear drift from the calibration procedures, and to implement this in the 
LabView program to display the “correct” real-time BGL measurement. (See: Results 
and discussion/Putting it all together – blood glucose regulation in diabetic pigs) 
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Another possible problem of all in vivo biosensors is interference from other 
compounds. The IvS-1 interferes with pH, and this leads to drifting, in this case from 
both swelling and shrinking. An internal unpublished in vitro study by InvivoSense 
examined the interference effect of 26 substances (drugs, nutrition and endogenous 
compounds) most relevant in an ICU setting. Of these, only pH was found to be 
clinically relevant. Currently, Dag Roar Hjelme and postdoc Sondre Volden are trying 
to construct a pH sensor based on the same smart-gel technology as the glucose sensor. 
The idea is to create a system that allows for auto-correction by putting the pH sensor 
and the glucose sensor in the same assembly. 
Studies of insulin pharmacology – a new approach to regulation 
The original idea for study II was to find an appropriate method for insulin 
administration that could take advantage of the sophisticated IvS-1 to regulate the BGL 
at the desired values. However, we soon realized that the traditional method using 
constant infusions of insulin was not leading us anywhere, as the time delays were 
substantial (Figure 2, Paper II). It did not make any sense to use a glucose sensor with a 
reaction time in the range from seconds to minutes and a regulation method with a time 
delay in the range from half-an-hour to two hours. In our despair, we realized that the 
only possible method that could lower the time delay to its minimum was the use of 
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intravenous boluses. From that moment, the sole perspective of the study was to 
characterize the attributes of intravenous insulin boluses. 2 
Thus, the primary aim of Paper II was to predict the time lags in the insulin/blood 
glucose system to find the appropriate times from an insulin bolus (IB) until predefined 
changes in BGL were observed. We defined a series of time variables (Figure 1, Paper 
II) and calculated their values with respect to different IB doses. Of most importance 
was the time from IB until first detectable decrease (Tdecr) and the time from IB until 
maximum rate of decrease (Tdecrmax). Since the BGL values were measured only in 
blood samples at an interval of one minute and with the ABL-720 analyzer only 
displaying the BGL values with one decimal place, there was some uncertainty 
regarding the absolute values. However, we reported in the paper that the Tdecr was 
approximately 3 to 4 minutes and the Tdecrmax was approximately 3.5 to 4.5 minutes. At 
this time, our group was convinced that a working AEP had to take advantage of IB as 
an alternative to constant infusions of insulin. Further work on the insulin algorithm is 
described in the next section. 
                                                 
2 The choice to later pulse the insulin administration in the AEP was therefore a result of the physiology 
we observed in the laboratory. Only later did we learn that this is the method by which the pancreas 
regulates BGL, and in fact is a prominent principle in several regulatory systems in the intact organism. 
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Putting it all together – blood glucose regulation in diabetic pigs 
The primary aim of the last study was to apply our theories of BGL regulation with IB 
in a more realistic model, i.e. diabetic pigs. In order to perform the experiment three 
preliminary tasks had to be accomplished: 
1) The insulin algorithm: Based on our experience from Paper II, we started to work on 
an insulin regulation algorithm. It was not at all clear what this should be like. The 
natural pancreatic beta cells display a regulatory rhythm, while the amount of insulin 
released by each pulse varies. We knew that an IB starts to lower the BGL in 
approximately five minutes, reaching a nadir in approximately 15 minutes. This meant 
that by using a fixed interval of five minutes (like a natural pancreas), several IBs would 
affect the BGL at a given time – which would be far too complicated at this stage. We 
therefore constructed a simplified system where the effect of each IB was followed 
throughout its effect period before a new IB was administered. An early theoretical 
sketch clarifying the idea is shown in Figure 4.
The fundamental principles (stated in Paper IV) were clear to us at that time (first 
establish glycemic control by constant insulin stress and then keep the BGL within 
target values to exploit the effect of consecutive IBs, the starting IB dose, the principle 
of halving and doubling based on the effect of the previous IB dose, timing by means of 
the IvS-1 monitor to allow the appropriate time until effect, etc.), and we made 
preliminary versions of the algorithm as flow charts. The flow charts were amended as 
the studies went on, and the current version is displayed in Figure 2, Paper IV. 
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3) Real-time BGL display: In order to conduct this study we needed the IvS-1 to display 
real-time BGL values, which was accomplished using the calibration procedures 
described in the Methodological considerations/The IvS-1 CGM section. This turned out 
to be very challenging for the engineers due to limitations in the original LabView 
application, the inherent instability/drift in the sensors, and very limited time and 
resources for software development before the study took place. DO was responsible for 
the hardware arrangement and software development, with some assistance from DRH, 
and the details of these complicated procedures are outside the scope of this thesis. 
Overall, the last study was successful in demonstrating the potential of our method of 
regulation. It was possible to reduce the BGL until it reached the target corridor rapidly 
and predictably, and to maintain the BGL within the corridor during most of the study 
period. The insulin algorithm was continuously refined as the studies went on, 
producing the best results in the last animals. The main problem in the study was 
difficulty with the real-time BGL display, which caused most of the inaccuracies in the 
results reported. The regulatory algorithm relies on very small changes in BGL, which 
means that the accuracy of the CGM is critical. Most of all, it is imperative that the 
CGM displays the correct direction of change in BGL at all times (i.e. whether the BGL 
is rising or falling) as a mistake in this parameter will result in incorrect conclusions. As 
such, our results indicate that the insulin algorithm is robust and has a high margin of 
safety. However, the algorithm is very demanding for the CGM.  
We chose to administer IBs as needed on the basis of the existing BGL value as an 
alternative to insulin pulses with constant timing, which would be closer to the actual 
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physiological situation (as described above). At the time, this was the only way to make 
the system work. The flip side of this method is that it probably results in larger 
amplitudes in BGL fluctuations than natural pancreatic oscillations do, because the 
carry-over effect of consecutive endogenous insulin pulses will smooth the BGL curve. 
However, the most important issue at the time was to determine whether this new 
regulatory principle could work at all. In the future, a model able to correct for, and take 
advantage of, this carry-over effect might be constructed, either by fixed interval IBs 
and/or IBs with a combination of a small continuous insulin infusion. The amplitude in 
BGL oscillations could probably be decreased, which would enable it to approach the 
physiological pattern found in intact organisms.   
During this project we did not have any formal collaboration with anyone who had 
cybernetic expertise.  We therefore had to explore the complicated world of control 
systems by ourselves and to try to understand how complex non-linear biological 
systems can be controlled. Our control method has little in common with the control 
systems most used by other groups, such as the PID and MPC controllers (See section 
Introduction/ Artificial endocrine pancreas). Our approach might be described as a 
heuristic control system, where our clinical understanding of the problem at hand 
coupled with common-sense understanding of the problem formed the basis for decision 
making. On the other hand, the system is more PID-like than MPC-like, because we did 
not try to model the system as such (we believe this is not possible, as described in the 
Introduction/glucose/insulin (patho-) physiology section), but only tried to respond to 
changes in BGL as they were coming from a black box. The major advantage of the 
heuristic approach over the PDI approach is that it eliminates uncertainties due to 
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parameter variations inherent in a PDI approach that operates with fixed control 
parameters. Thus, the heuristic approach is more robust and can likely be applied to any 
group of patients once the control objectives are properly set. Another possible way to 
optimize a PID system is to use adaptive control where the control parameters are not 
fixed but can adapt to changing situations.   
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Conclusions – answers to the aims 
I will conclude this thesis by addressing the aims stated in the beginning of the paper. 
Aim 1: To test whether a novel intravascular continuous glucose monitor could 
measure blood glucose with highly accurate results and almost no time delay. To 
further develop the system to provide real-time readouts of the current blood glucose 
level. 
Paper I showed that the IvS-1 measurements were in high agreement with the blood 
glucose values obtained from the ABL 720 machine, and that the sensor reacted rapidly 
within minutes. Later experiments with the sensor and unpublished measurements of the 
sensor performance have shown us that the reaction time is on the order of seconds to 
minutes in a clinical setting of blood glucose control. In practical use, the IvS-1 seems 
to be able to detect very small changes in BGL, much smaller than the 0.1 mmol/l cut-
off value provided by the blood gas machine. The principles for the pre-insertion in
vitro calibration and the repetitive in vivo one-point calibration of the IvS-1 sensors 
were developed and applied in Paper IV. However, the system did not perform 
satisfactorily, and merits further research. The problems could be caused by technical 
issues related to the pre-insertion calibration procedure, software issues, the need for 
continuous pH correction, or issues regarding the background swelling (stability) of the 
gel. 
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Aim 2: To determine the inherent lag time in the insulin/blood glucose system. To use 
this information to make a new algorithm for rapid and predictable blood glucose 
control.
In Paper II we found that insulin bolus injections in previously healthy pigs yielded a 
first detectable decrease in BGL in 2 to 6 minutes, a maximum rate of decrease shortly 
thereafter and a nadir value in 15 – 20 minutes. In Paper IV we confirmed these finding 
in diabetic pigs. The time intervals seemed to be consistent while the overall response 
was naturally dependent upon the insulin dose. We used this information and coupled it 
with the knowledge of physiological pulsed insulin secretion from the endocrine 
pancreas to make a new algorithm for insulin control. The principle ideas behind the 
algorithm were born during the experiments leading to Paper II, while the details were 
constantly refined during the experiments for Paper IV up to and including the current 
version. 
Aim 3: To get a firm idea of the pros and cons of glucose monitor positioning in 
different intravascular locations. 
Paper I showed the benefit of using intravascular monitor positioning. In Paper III we 
found that the blood glucose value is the same in mixed venous and arterial blood. In 
our first studies (Paper I) we mostly used central venous positioning, while in later work 
we preferred intra-arterial positioning. We considered the latter approach to be 
preferable, as it seemed to lead to enhanced sensor performance with less clotting. 
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Future studies using this model will therefore rely on intra-arterial sensor positioning 
only. 
Aim 4: To establish a diabetic pig model. 
We were able to establish a satisfactory diabetic model for our purpose by using 
streptozotocin. However, this method is expensive when the animal is only used once 
(acute experiment), and we will therefore continue to search for simpler and cheaper 
methods to block endogenous insulin production during acute experiments. An 
alternative is to construct robust long-lasting models by inducing diabetes in miniature 
pigs and use these in repetitive less-invasive studies. 
Aim 5: Putting it all together: using the newly adapted glucose control algorithm and 
the intravascular continuous glucose monitor to regulate blood glucose levels in 
diabetic pigs. 
The entire effort that led to this thesis, with studies in a variety of scientific fields within 
physiology, pharmacology, in vivo biosensing, material physics and control theory, 
combined with a range of technical challenges and difficulties, merely served to answer 
one question: Is it really possible to construct a fully automatic artificial pancreas? As a 
result of my research, I would say that in theory, it is. However, there are several 
obstacles. First of all, it will require an absolutely reliable, accurate biosensor that reacts 
rapidly, and that has the properties described in the Results and discussion/Validation of 
the IvS-1 section. Secondly, this sensor has to be positioned in an intravascular 
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compartment to avoid delays in the readings of the actual glucose levels. To minimize 
any kind of bio-incompatibility and bio-fouling, we believe the best site is intra-arterial 
(at least with the current technology). Thirdly, the insulin has to be delivered 
intravenously (peripherally, in the central caval or probably best in the portal vein). 
Fourthly, the insulin delivery has to be pulsed either by our method, a more 
physiological “correct” rhythm with stable pulses, or alternatively in a combination of 
constant infusion and pulses. Paper IV showed that these principles do work in a short-
term experiment, as we were able to control the BGL (almost) as intended. 
Nevertheless, producing a stable long-term implantable AEP remains a great challenge.
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Issues for further research 
As described in the Results and discussion/Validation of the IvS-1 sensor section, there 
are five attributes of the CGM that seem to be important for its optimal performance: 
accuracy, response time, bio-compatibility, stability and interference. As described in 
this thesis, the current challenge relates to issues of stability and interference. Current 
and future research should focus on pH stability (possibly with the addition of a pH 
sensor) and minimizing the drift by using alternative hydrogels (or at least to make the 
drift more linear and predictable). In addition, both the hardware and the software that 
run the IvS-1 system have to be upgraded. The data acquisition software was not 
optimized for real time calibration and compensation. This became evident while the 
engineers were trying to twist the program to display real-time BGL for the experiments 
in Paper IV; reprogramming of the LabView application is a necessary first step for this. 
We also need to take a closer look at the whole calibration procedure and the set-up for 
pre-insertion in vitro calibration. 
The next step is a total assembly of the AEP system. In the studies presented here, a 
syringe pump administered the IBs, which were manually adjusted in accordance with 
the insulin algorithms. The algorithm should be programmed using the same LabView 
application that runs the IvS-1 system and should be hard-wired to a syringe pump 
controlled by the software. From this point we will have a nice working system to 
perform new animal studies, the algorithms could then be further refined and the long-
time stability and bio-compatibility of the glucose sensors could be tested. 
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From this point there are at least two possible roads to follow: 1) assembling and testing 
of the currently developed and/or a similar system in humans and 2) minimizing the size 
of the hardware approaching an implantable AEP to be tested in animals.   
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Pharmacology of Intravenous Insulin Administration:
Implications for Future Closed-Loop Glycemic Control
by the Intravenous/Intravenous Route
Nils K. Skjaervold, M.D.,1,2 Oddveig Lyng, M.Sc.,3 Olav Spigset, M.D., Ph.D.,4,5 and Petter Aadahl, M.D., Ph.D.1,2
Abstract
Background: Our group is attempting to construct an artiﬁcial pancreas based on intravenous glucose moni-
toring and intravenous insulin delivery. To do so, the pharmacology of intravenous insulin administration must
be studied. We used a pig model to determine the inherent lag time in the insulin/blood glucose system. The
goal was to suggest a method that reduces the blood glucose level in a rapid and yet predictable manner.
Methods: Six pigs received continuous intravenous insulin infusions at 0.04, 0.08, or 0.4 IU/kg/h for 60min. Two
pigs received short-term intravenous infusions at 0.4 IU/kg/h for 2min, repeated ﬁve times at 60-min intervals.
Four animals received ﬁve intravenous insulin bolus injections at 60-min intervals, two at 0.01 IU/kg and two
0.02 IU/kg, with a ﬁnal dose of 0.04 IU/kg. The blood glucose level was measured every 1–5min.
Results: A high rate of intravenous insulin infusion led to rapid declines in blood glucose levels. The same rapid
decline was achieved when the infusion was halted after 2min. Using the latter method and with intravenous insulin
boluses, bloodglucose levels started to rise again after approximately 15–20min. Insulin boluses led to a ﬁrst detectable
decrease in blood glucose level after 2–6min and to a maximum rate of decrease shortly thereafter.
Conclusions: We found that intravenous bolus injections of insulin lowered blood glucose levels rapidly and
predictably. Repetitive small intravenous insulin boluses together with an accurate and fast-responding intra-
vascular continuous glucose monitor should be studied as a method of closed-loop glycemic control.
Introduction
The development of an artiﬁcial endocrine pancreashas been a major research area in diabetes care for over
50 years. It consists of a continuous glucose monitor, an in-
sulin infusion system, and a control algorithm, assembled as
a closed-loop regulatory system with no need for manual
adjustments. The Biostator (Miles Laboratories, Elkhart, IN)
was constructed in the late 1970s, as a system that combined
continuous blood sampling analyzed ex vivo with automated
intravenous insulin infusion.1 The system performed very
well but was hampered by its large, bulky size, its invasive-
ness, and the need to immobilize the patient. In the past
20 years most research has been focused on subcutaneous
continuous glucose monitoring and subcutaneous insulin
administration.2 Despite considerable effort and abundant
use of resources on establishing fully automated blood glu-
cose regulation by this route, success has been elusive. At the
turn of the century, blood glucose control in the intensive care
setting awakened substantial interest because of studies de-
scribing its beneﬁcial role on intensive patient outcome.3–5
This led to a renewed interest inmore invasive and aggressive
methods of glucose control, reopening the intravenous route
to both insulin administration as well as glucose monitoring.
We have previously described a novel intravascular con-
tinuous glucosemonitor ideal for intensive care use.6 Our goal
is to further develop this technology into a fully automatic
closed-loop regulatory system, primarily for improved blood
glucose control in intensive care patients and subsequently as
a solution for outpatient diabetes care. An obvious advantage
of using intravenous monitoring and insulin delivery—as
opposed to the subcutaneous route—is to minimize the time
lag between glucose monitoring and insulin delivery and be-
tween insulin delivery and the time a new blood glucose level
(BGL) is reached. The time lag problem is a serious challenge in
subcutaneous/subcutaneous closed-loop regulatory systems,
calling for complicated mathematical modeling of the insulin
control algorithm.7 Even so, there is also a time lag issue with
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the intravenous route. We have observed—both clinically and
in animal models—that continuous intravenous insulin infu-
sions reduce the BGL in a rather slowand unpredictableway. It
is difﬁcult notably to rapidly lower the BGL without drifting
into hypoglycemia. The elimination half-life of insulin is re-
ported to be approximately 6min;8 however, there are no re-
ports on the lag time from intravenous insulin administration
until a decrease in BGL is observed.
To take full advantage of the intravenous/intravenous
route of blood glucose control, the pharmacology of intrave-
nous insulin administration must be studied. The aims of this
study were to use a pig model to determine the inherent lag
time in the insulin/blood glucose system and to suggest a
method of insulin administration that reduces BGLs in a
rapid and yet predictable manner.
Materials and Methods
Animals
The study was approved by the Norwegian State Commis-
sion for Animal Experimentation. Twelve pigs (weighing 24–
32kg) were acclimatized and treated in accordance with the
European Convention for the Protection of Vertebrate Animals
Used for Experimental and Other Scientiﬁc Purposes. The pigs
were premedicated with intramuscular diazepam (0.4mg/kg)
(Stesolid, Dumex-Alpharma, Copenhagen, Denmark) and
azaperon (12mg/kg) (Stresnil, Janssen-Cilag, Vienna,
Austria). Anesthesia was induced with intravenous atropine
(0.04mg/kg) (Nycomed Pharma AS, Oslo, Norway), ketamine
HCl (10mg/kg) (Parke-Davis, Solna, Sweden), and thiopental
sodium (5mg/kg) (Pentothal, Abbott Scandinavia AB, Solna,
Sweden).
The animals were tracheotomized through amidline surgical
cut-down and mechanically ventilated and monitored on an
anesthesia machine (Aisys, GE Healthcare Technologies, Oslo).
The fraction of inspired oxygenwas kept at 0.3, the tidal volume
was kept at 10mL/kg, and minute ventilation was adjusted to
maintain an arterial partial pressure of CO2 of 4.5–5.5 kPa. An-
esthesia was maintained by isoﬂurane (0.5–1.0%) (Forene,
Abbott ScandinaviaAB) and an infusion of intravenous fentanyl
(at 7lg/kg/h) (Pharmalink, Spanga, Sweden). Fluid balance
was achieved using a continuous infusion of heated (37C)
Ringer’s acetate at 5mL/kg/h. The insulin used in the study
was recombinant human insulin (Actrapid, Novo Nordisk,
Bagsværd, Denmark). The animals were euthanized with
an overdose of pentobarbital (pentobarbital NAF, Apotek,
Lørenskog, Norway) at the end of the study.
An intra-arterial line was placed in the right carotid artery
via the tracheotomy wound for monitoring and blood sam-
pling. An intravenous line was placed in the right internal
jugular vein through a separate surgical cut-down. The
bladder was exposed through a small laparotomy incision for
the insertion of a bladder catheter. Glucose was measured in
whole arterial blood with a blood gas analyzer (ABL 725,
Radiometer, Brønshøy, Denmark). All animals were allowed
to rest for at least 60min to stabilize their BGL before the
administration of insulin.
Study protocol
Continuous intravenous insulin infusions. Six pigs were
assigned to receive a continuous intravenous insulin infusion
of 0.04, 0.08 (‘‘clinical’’ doses), or 0.4 (a high dose) IU/kg/h
(two pigs in each group) for 1 h. Glucose measurements were
performed every 5min throughout the 1-h study period.
Short-term intravenous insulin infusion. After a prelimi-
nary analysis of the continuous insulin infusion group, two
animals were assigned to receive a continuous intravenous
insulin infusion of 0.4 IU/kg/h insulin for 2min (a total of
0.013 IU/kg). This infusion was repeated ﬁve times at 60-min
intervals. Glucose measurements were performed every 2–
5min throughout the 5-h study period.
Intravenous insulin boluses. After preliminary analyses
of the continuous and short-term intravenous insulin infusion
groups, four animals were assigned to receive repetitive in-
travenous insulin bolus injections. Based on ﬁndings from the
studies with insulin infusions and pilot animals, we chose
0.01, 0.02, and 0.04 IU/kg in alternate doses with 60-min in-
tervals. Five intravenous insulin boluses were given to each
animal, two at 0.01 IU/kg and two at 0.02 IU/kg in a ran-
domized order and then a ﬁnal dose of 0.04 IU/kg. Glucose
measurements were performed every 1–5min throughout the
5-h study period, with the most frequent sampling during the
ﬁrst 10min after each bolus.
Blood glucose analysis
To analyze BGL we used arterial blood samples on a
Radiometer ABL 725 blood gas analyzer. In this instrument,
glucose is transported across the outer membrane of a
multilayer glucose electrode. The glucose oxidase that is
immobilized between the inner and outer membrane layers
converts glucose to hydrogen peroxide (glucose +O2/
gluconic acid +H2O2), which crosses the inner membrane
toward the electrode’s anode. The oxidation of hydrogen
peroxide creates an electric current that is proportional to
the amount of hydrogen peroxide available and hence is
proportional to the amount of glucose in the sample. In
addition, the analyzer also uses different electrodes with
similar techniques to measure partial pressure of O2, partial
pressure of CO2, pH, and lactate.
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Calculations and statistics
Glucose measurements from the continuous and short-term
insulin infusion groupswere collected andplotted against time.
No further statistical analyses were performed on these data.
Six variables were derived from the bolus injection part of the
study (Fig. 1). The timeuntil the ﬁrst detectable decrease in BGL
(Tdecr) was deﬁned as the time between the intravenous insulin
bolus administration and a reduction in BGL of ‡ 0.1mmol/L
that was not followed by a rise in BGL above this value within
the next 5min. The maximum rate of decrease (MRD) was
calculated using linear regression as follows: individual
slopes were constructed using all possible sets of ﬁve con-
secutive data points in the time series, and then the steepest
line was chosen and reported as MRD. The time until MRD
(Tdecrmax) was deﬁned as the time between intravenous insulin
bolus administration and the ﬁrst data point used when calcu-
lating MRD. The maximum decrease in BGL (DCmax) was de-
ﬁned as the difference in BGL between baseline and the lowest
BGLmeasured within the next 55min. The time until the lowest
measured BGL (Tmin) was deﬁned as the time from the intra-
venous insulin bolus administration until DCmax was achieved.
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As an overallmeasure of the effect of insulin on BGLwe also
calculated the area corresponding to the drop in the BGL curve
for the ﬁrst 30min after the intravenous insulin bolus ad-
ministration (area over the curve from 0 to 30min [AOC0–30])
using the trapezoidal rule (gray shading in Fig. 1). Thirty
minutes was chosen as the time frame because the insulin
effect seemed to fade after this period, an observation that is in
accordance with the previously reported elimination half-life
of insulin of approximately 6min.8 Thus, further changes in
BGL (increases or decreases) after 30minwould be expected to
be a result of the general oscillations of the BGL curve rather
than a result of the previous insulin dose.
The statistical analysis was conducted using R software,
version 2.10.1 (R Foundation for Statistical Computing,
Vienna, Austria). We compared the effect of the three dose
levels of insulin as ﬁxed factors on the six deﬁned outcome
variables using linear mixed-effect models (the lme function
from the nlme package), thereby adjusting for nested sampling
from four different animals.
Results
Continuous intravenous insulin infusion
Intravenous insulin infusion led to a dose-dependent sig-
moid-shaped decrease of the BGL (Fig. 2). The BGLs de-
creased throughout the study time of 60min.
Short-term intravenous insulin infusions
Short-term intravenous insulin infusions produced a rapid
BGL decline similar to that caused by high-rate continuous
intravenous insulin infusions. The BGLs reached a nadir at
approximately 15–20min before returning to their baseline
value (Fig. 3).
Intravenous insulin boluses
The BGL curves of each of the four animals are shown in
Figure 4. All insulin doses led to a detectable fall in BGL. The
BGL of one animal fell to hypoglycemic values after the fourth
bolus dose, making the animal unsuitable for further study.
This exclusion left us with the following data: eight boluses in
four animals of 0.01 IU/kg, seven boluses in four animals of
0.02 IU/kg, and three boluses in three animals of 0.04 IU/kg.
Results for the six outcomevariables are presented inTable 1.
Tdecr appeared within 5min for all but one of the boluses, for
which the change was apparent after 6min. There was no sig-
niﬁcant difference inTdecr between thevariousdoses.MRDwas
high at all doses and was also signiﬁcantly dose-dependent.
Tdecrmaxwas not found to be dose-dependent.DCmaxwas found
to be highly and signiﬁcantly dose-dependent, whereas there
was no signiﬁcant difference between the different doses for
Tmin. AOC0–30 was highly and signiﬁcantly dose-dependent.
To provide a visual comparison of the various bolus and
continuous infusion doses, the valueswere converted to ratios
by dividing each BGL value with its respective baseline BGL
value (Fig. 5).
Discussion
The principal ﬁnding of this study is that intravenous in-
sulin infusion at ‘‘clinical’’ rates (i.e., 0.04–0.08 IU/kg/h) led
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FIG. 1. The six variables derived from intravenous insulin bolus injections at time = 0.DCmax, maximum decrease in blood
glucose level; MRD, maximum rate of decrease (linear regression using ﬁve consecutive observations [black circles] for all
possible combinations and choosing the steepest regression line); Tdecr, time until the ﬁrst detectable decrease in blood
glucose level; Tdecrmax, time until the maximum rate of decrease; Tmin, time until the lowest measured blood glucose level.
Gray shading marks the area of the drop in the blood glucose curve for the ﬁrst 30min after insulin bolus injection (AOC0–30).
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FIG. 2. Blood glucose levels after continuous intravenous insulin infusion in six pigs. Each of the six animals is depicted
with a separate curve. Two animals were given a dose of 0.04 IU/kg/h (open circles), two animals were given 0.08 IU/kg/h
(open triangles), and two animals were given 0.4 IU/kg/h (closed squares).
Time (min)
2
3
4
5
6
7
8
0 60 120 180 240 300
Bl
oo
d 
gl
uc
os
e 
le
ve
l (m
mo
l * 
L-
1 )
FIG. 3. Repetitive short-term intravenous insulin infusions in two pigs. Each animal received 0.4 IU/kg/h for 2min (a total
of 0.013 IU/kg) six times with 60-min intervals between each infusion. The periods of insulin infusions are marked with gray
shading.
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BGLs to decline slowly. To achieve more rapid changes, the
infusion rate had to be increased to very high levels, which led
to a sustained depression of the BGL. By halting the high rate
infusions after 2minwe achieved the same rapid decline, with
BGL reaching a nadir within 15–20min, and then a rise in the
BGL toward baseline values without drifting into hypogly-
cemia. We hypothesized that a 2-min infusion would not be
very different from a bolus injection, and so we continued
working with boluses. This has the advantage that one only
needs to manipulate one variable (the dose), compared with
short-term infusions where there are two (the dose and the
infusion time).
Intravenous insulin bolus administration led to a detectable
decrease in BGL after a time interval of 2–6min and to a
maximum rate of decrease shortly thereafter. Neither the Tdecr
nor the Tdecrmax was found to be dose-dependent. However,
this ﬁnding could be due to a type II error caused by the low
number of animals in the study, and both Table 1 and Figure 5
indicate a trend toward a shorter time until the maximum rate
of decrease for the highest bolus dose. Intravenous insulin
boluses resulted in a dose-dependent reduction in BGLs with
regard to both the maximum decrease and the area of the
decline under the BGL curve. Figure 5 shows the effect of an
intravenous bolus injection of insulin on the relative changes
in BGL compared with that of intravenous insulin infusion.
The rapid onset and the predictable and short-lasting effect of
the boluses at the doses chosen are clearly evident. In partic-
ular, the difference between administering 0.04 IU/kg as a
bolus (closed squares) and as a 1-h infusion (upper margin of
the gray shading) is striking.
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FIG. 4. Blood glucose level curves in four pigs receiving repetitive bolus doses of intravenous insulin. The timing of the insulin
boluses is indicated with arrows. The insulin doses were given in the following sequence: (0.01+ 0.02+ 0.01+ 0.02+ 0.04) IU/kg
in two animals (open circles) and (0.02+ 0.01+ 0.02+ 0.01+ 0.04) IU/kg in two animals (closed squares).
Table 1. The Six Outcome Variables from the Intravenous Insulin Boluses
Insulin dose (IU/kg)
0.01 0.02 0.04 P value
Tdecr (min) 3.88 (0.64) 4.00 (1.41) 3.33 (0.58) 0.32
MRD (mmol/L/min) 0.098 (0.010) 0.10 (0.030) 0.14 (0.017) 0.027
Tdecrmax (min) 4.50 (1.41) 4.57 (1.33) 3.67 (1.15) 0.74
DCmax (mmol/L) 0.73 (0.14) 1.10 (0.37) 1.57 (0.058) < 0.001
Tmin (min) 16.1 (4.6) 18.6 (5.6) 21.7 (7.6) 0.46
AOC0–30 (mmol/L/min) 9.42 (3.63) 18.51 (6.47) 27.82 (2.48) < 0.001
All data are mean (SD) values.
P values are from comparisons using linear mixed-effect models.
AOC0–30, area over the curve from 0 to 30min; DCmax, maximum decrease in blood glucose level; MRD, maximum rate of decrease; Tdecr,
time until the ﬁrst detectable decrease in blood glucose level; Tdecrmax, time until maximum rate of decrease; Tmin, time until the lowest
measured blood glucose level.
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The pancreas does not secrete insulin into the portal
bloodstream continuously, but rather in pulses at 5-min in-
tervals. The amount of insulin secreted in each pulse is
primarily regulated by changes in the blood glucose concen-
tration; when the BGL is rising, more insulin is secreted with
each pulse, andwhen the BGL is falling, less insulin is secreted
with each pulse.10,11 This principle causes tiny ﬂuctuations of
the normal blood glucose curve.12 If a closed-loop system
were to resemble nature as closely as possible, it would
therefore secrete insulin in pulses at 5-min intervals, as de-
scribed above and as proposed in a recent article.13 With the
current knowledge, we still ﬁnd this to be too complex.
However, we do believe it should be possible to construct a
closed-loop system using repetitive small boluses of intrave-
nous insulin together with an accurate and fast-responding
intravascular continuous glucose monitor. The timing of the
bolus injections would be determined by the BGL curve, and
the dose of the intravenous insulin boluses would be calcu-
lated based on the history of the previous boluses and their
effect on the BGL curve, thereby allowing tiny oscillations in
BGL, ideally with amplitudes of approximately 0.5mmol/L.
The strength of this study lies in the use of a model with
large animals that resemble humans, which allowed us to
obtain numerous consecutive blood samples from each ani-
mal and to manipulate BGLs without fear of the implications
of hypoglycemia. The major weaknesses include our use of a
pig model and the fact that the animals were healthy and did
not have diabetes. However, we believe that the fundamental
principles from our ﬁndings will be applicable to humans
with diabetes, although this issue merits further examination.
Another limitation was the choice to give the largest bolus
dose only at the end of each experimental course. This pro-
cedure was chosen becausewewere uncertain whether such a
high dose would inﬂuence the effect of subsequent insulin
doses. Finally, the number of pigs examined was low, leading
to a risk of type II errors when comparing the different doses.
Nevertheless, we believe that this study provides sufﬁcient
data to form the basis for performing carefully controlled
studies with bolus doses in humans.
In conclusion, we found that continuous intravenous in-
fusion of insulin at normal ‘‘clinical’’ doses leads to slow
changes in the BGLs due to the inherent lag time in the
insulin/blood glucose system. In contrast, bolus injections of
insulin lowered BGLs rapidly and predictably. In the future,
closed-loop glycemic control might be achieved by using
repetitive small boluses of intravenous insulin together with
an accurate and fast-responding intravascular continuous
glucose monitor.
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Intravenous Bolus Insulin Delivery:
Implications for Closed-Loop Control and Hospital Care
Irl B. Hirsch, M.D.
Intravenous insulin infusion to treat diabetic ketoaci-dosis has been one of the cornerstones of therapy since the
1920s. Few appreciate that this route of insulin delivery was
not approved by the U.S. Food and Drug Association until
2005. Evenmore surprising are theminimal published data on
the kinetics of intravenous insulin, by either intravenous in-
fusion or intravenous bolus. Most appreciate that the actual
pharmacokinetics of intravenous insulin are quite short, but it
was quite surprising to learn the pharmacodynamics may be
longer than appreciated.1 However, those who previously
worked with the Biostator (Ames Division, Miles Labora-
tories, Elkhart, IN) in the late 1970s and 1980s saw ﬁrsthand
how slow intravenous insulin could be.2
The precise action times of intravenous insulin have taken
on greater interest with the goal of developing an artiﬁcial
pancreas. The real problem is the painfully slow pharmaco-
dynamics of our current ‘‘rapid-acting’’ subcutaneous insu-
lin.3 If a safe and effective system using intravenous insulin
could be developed for an artiﬁcial pancreas, waiting for a
faster subcutaneous insulin analog wouldn’t be required.
The article by Skjaervold et al.4 provides us with a better
understanding about the time–action proﬁle of intravenous
insulin. In some respects, it is surprising it has taken so many
decades for this type of work to be completed. On the other
hand, intravenous insulin is still rarely used today, although
given themore common use of intravenous insulin infusion in
the hospital this route of therapy is more often used now than
in past decades.5 It should also be appreciated that the infu-
sions and boluses done by Skjaervold and co-workers were
performed in a pig model, and thus human studies should be
considered before serious attention is paid to the use of in-
travenous insulin in a closed-loop system.
The ﬁndings by the study by Skjaervold et al.4 can be
summarized as follows: (1) Despite the short half-life of in-
travenous insulin, when it is infused at rates up to 0.08 IU/
kg/h blood glucose declines slowly. (2) Higher rates lead to
more rapid decreases in blood glucose, but eventually hypo-
glycemia will ensue. (3) Hypoglycemia can be prevented with
these higher rates of infusion leading to quicker reduction of
blood glucose if the infusion lasts for only 2min. (4) In-
travenous bolus insulin at doses of 0.01–0.04 IU/kg results in
a decrease in blood glucose on average at 4min. (5) With
intravenous bolus insulin there appears to be a clear dose
dependency for degree and length of glucose level lowering.
(6) Because of the short glucose response of the intravenous
bolus, hypoglycemia as seen with the intravenous infusion
after 30min does not occur.
What are the major implications of these results? First, it is
unlikely that subcutaneous insulin will ever have effects as
quick as intravenous insulin. For a closed-loop system, in-
travenous bolus insulin appears to have desirable kinetics,
although many future studies in humans will need to conﬁrm
these initial ﬁndings. Although we are obviously a long way
from the use of outpatient intravenous bolus insulin in a true
‘‘artiﬁcial pancreas,’’ insulin provided by this route could
possibly be used in a standardized manner for inpatients.
Intraoperative blood glucose control by anesthesiologists is
frequently performedwith intravenous bolus insulin, yet I am
not aware of insulin kinetic data, safety, or efﬁcacy studies
using insulin in thismanner. In fact, mymain concernwith the
use of intravenous bolus insulin in any part of the hospital is
that these patients often have poorly controlled diabetes with
resultant potassium, magnesium, and phosphate deﬁciency.
The use of intravenous bolus insulin in this population may
actually be quite dangerous. At the very least, intravenous
bolus insulin should be speciﬁcally studied in different patient
populations (speciﬁcally, levels of glycemic control) in the
hospital, including the operating room.
Next, assuming the data from Skjaervold and colleagues
can be repeated and conﬁrmed in humans, for a closed-loop
system having such a quick and effective insulin delivery will
require an equally rapid glucose sensor without a lag time.
This is unlikely to occur with interstitial glucose measure-
ment, and thus an intravascular glucose sensor will be re-
quired. Like the intravenous bolus insulin delivery, besides a
closed-loop implication for type 1 diabetes, there are also in-
patient implications if this type of sensing device can be per-
fected. Indeed, it is likely an inpatient intravascular sensor
used in combination with intravenous bolus insulin is a more
realistic initial goal, depending on the duration the sensor
lasts and the ease of delivering the insulin.
Finally, besides repeating these intravenous bolus insulin
studies in humans, itwill be interesting to perform these studies
speciﬁcally in individuals with type 1 diabetes. Besides asses-
sing ﬂuxes of potassium, magnesium, and phosphate, close
attention to electrocardiogram changes will be required. In
particular, patients with long-standing diabetes with coronary
artery disease should be studied to ensure safety. Other
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metabolites such as free fatty acids and b-hydroxybutyrate
should also be assessed. We would expect complete suppres-
sion of lipolysis with intravenous bolus insulin, but it likely
depends on the frequency with which the insulin is provided.
Although it is too soon to know if intravenous bolus insulin
will someday be used for a closed-loop system, the study by
Skjaervold et al.4 gives us initial and important information
about the glycemic impact of this type of insulin delivery.
Hopefully these studies can be repeated in humanswith a true
real-time intravascular sensor so that the elusive goal of an
artiﬁcial pancreas can be achieved. Although not mentioned
by the authors, these data could have important impact for the
use of insulin in the hospital. As we approach the centennial
birthday of the discovery of insulin, it seems appropriate to
ﬁnally understand the best way to use intravenous insulin.
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ABSTRACT 
 
Objective: The goal of our group is to construct an artificial endocrine 
pancreas based on intravenous glucose monitoring and intravenous insulin 
administration. The intravenous approach minimizes time delays, which 
makes the regulatory algorithm much easier. The aim of this study was to 
construct a glucose regulatory algorithm by employing the natural pulsatile 
pattern of insulin secretion and the oscillatory pattern of resting blood glucose 
levels and further to regulate the blood glucose level in diabetic pigs by this 
method. 
 
Design: An intervention study in pigs. 
 
Setting: Animal laboratory in a university hospital. 
 
Subjects: Four healthy pigs. 
 
Interventions: We developed a control algorithm based on repetitive 
intravenous bolus injections of insulin and combined this with an intravascular 
blood glucose monitor. Four anesthetized diabetic pigs were used in the 
study, instrumented with the intravascular blood glucose monitor and 
regulated according to our algorithm. 
 
Measurements and Main Results: The animals developed a mildly diabetic 
state from streptozotocin pre-treatment (with a starting blood glucose level 
 ͷ
7.46 to 14.06 mmol/l). They were steadily brought within the target range of 
4.5 – 6.0 mmol/l in 21 to 121 min and kept within that range for 128 to 238 
min. The period with hypoglycemic values varied from 2.9 to 51.1 min, which 
put the levels in the correct range from 73 to 99%.  
 
Conclusions: The study confirmed our hypotheses regarding the feasibility of 
this new principle for blood glucose control, and the algorithm was constantly 
improved during the study to produce the best results in the last animals. The 
main obstacles were the drift of the IvS-1 sensor and problems with the 
calibration procedure, which calls for an improvement in the sensor stability 
before this method can be applied fully in new studies in animals and humans. 
 
  
6
INTRODUCTION
 
The development of an artificial endocrine pancreas (AEP), composed of a 
system of continuous blood glucose monitoring and automated insulin 
infusion, has been a long sought-after solution in diabetic care (1). Current 
research is focused on subcutaneous glucose measurements and 
subcutaneous insulin administration (2). However, the performance of these 
systems are still less than satisfactory, and the reality of a working AEP 
remains elusive. 
 
A novel intravascular continuous glucose sensor, the IvS-1 (Invivosense, 
Trondheim, Norway), has been constructed using smart-gel technology. The 
sensor material consists of a hydrogel that incorporates boronic acid 
molecules that shrink and swell in response to the surrounding glucose 
concentration. The gel is assembled on the tip of an optical fiber, and the 
monitor employs optical interferometry to measure very small changes in gel 
size (3). Our group has tested the IvS-1 in preclinical in vivo studies in pigs, 
and found that it demonstrated high accuracy and a rapid response time (4).  
 
(Figure 1 here) 
  
The sensor was originally developed to meet the need for better control of 
blood glucose levels (BGL) in patients in intensive care units. However, when 
we discovered the potential of our technology we started to work towards the 
development of an AEP. We realized that the sensor was able to 
 ͹
instantaneously detect very small changes in BGL, and we found small 
oscillations in BGL with a period of approximately 10 minutes. 
 
Recent research has demonstrated the pulsatile nature of pancreatic beta 
cells. A convincing body of evidence indicates that insulin is secreted in 
synchronized bursts from the entire pancreas into the portal blood stream 
(5)(6)(7). Likewise, multiple studies in humans and animals have described 
the oscillatory nature of systemic levels of blood glucose and insulin 
(8)(9)(10)(11). Pulsatile pancreatic activity seems to be lost in advanced type 
2 diabetes (12). Pulsed intravenous insulin delivery has been shown to be 
more effective in lowering BGL compared to equal doses of continuously 
infused insulin (13)(14), and the pulsatile nature of endogenous insulin 
secretion has been mimicked for therapeutic reasons as pulsatile intravenous 
insulin therapy. Compared to standard therapy, pulsed therapy has shown 
better metabolic control, less end-organ damage and restoration of normal 
pulsatile pancreatic function in type 2 diabetes (15)(16)(17). 
 
When we first started to infuse insulin intravenously to regulate BGL, we 
found that the time from start of the infusion until a new steady state BGL was 
reached to be two hours or longer, which is very long. This means it would 
take several hours to adjust any insulin infusion to the correct rate to achieve 
an appropriate and stable BGL. The insulin resistance in a single individual is 
constantly changing (18), and some authors even suggest that the regulatory 
system includes deterministic chaotic components that would render it 
impossible to foresee the effect of insulin on BGL during a given time using 
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ordinary linear methods (19). A control system based on continuous infusions 
will therefore always be “running to catch up” and will have great difficulties in 
lowering a patient’s BGL to a sufficient degree without risking hypoglycemia. 
The use of subcutaneous sensors and infusions would increase the time 
delay and complicate the situation even more. 
 
Given this background, we conducted a series of experiments to characterize 
the effects of intravenous bolus injections of insulin (IB) in a previous study 
(20). Here, we found the time lag from an IB until a first observed decrease in 
BGL to be four to six minutes. The maximum rate of decrease in BGL 
occurred shortly thereafter, and a nadir was reached 15 – 20 minutes after the 
IB. These time intervals seemed to be rather dose-independent – as long as 
the IB dose was sufficient to yield any change in BGL at all. 
 
Based on these observations, we hypothesized that it should be possible to 
construct an AEP using the biological pancreas as a model. The IvS-1 would 
detect early changes in BGL, and the system should respond instantaneously 
with adjusted repetitive IBs. We had to construct a novel algorithm with the 
target of establishing and maintaining a normal fasting BGL, defined as 4.5 – 
6.0 mmol/l. BGL regulation had to be a two-stage process, with the first step 
to establish glycemic control in a hyperglycemic subject by rapidly bringing 
BGL to the desired level, and thereafter to maintain the desired glucose level 
over time.  
 ͻ
MATERIALS AND METHODS 
 
The insulin algorithm and administration 
We identified the following key elements that had to be incorporated in the 
algorithm: 
1) The overall goal was to bring BGL to within a predefined range of 4.5 – 
6.0 mmol/l and to keep it in this range, including small oscillations 
around the middle value in this range. 
2) IB was administered whenever needed in accordance with the 
continuous BGL readings; adjusting the IB doses was kept simple with 
only three alternatives according to the previously administered IB: the 
same dose as the previous one, half the previous dose or twice the 
previous dose. 
3) Any decrease in BGL should be observable within five minutes after an 
IB, otherwise a new IB should be administered. 
4) Blood glucose control should be established by a rapid decrease in 
BGL from hyperglycemic levels with a series of consecutive IBs. The 
BGL should be lowered  1 mmol/l for each IB injected. 
5) As soon as the BGL dropped below 6.0 mmol/l, blood glucose control 
should be maintained by meticulously timed IBs to allow small 
fluctuations in the blood glucose curve. 
 
The insulin algorithm was constructed as a flowchart based on simple IF- 
THEN decisions, and the details of the algorithm evolved as the study went 
on. The current version of the algorithm is shown in Figure 2. 
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(Figure 2 here) 
 
Human recombinant insulin 0.1 IU/ml (Actrapid,NovoNordisk, Bagsværd, 
Denmark) was used in the study. The drug was manually administered from a 
syringe pump (using the bolus function) in accordance with the insulin 
algorithm.  
 
 
The animal model 
 
The study was approved by the Norwegian State Commission for Animal 
Experimentation. Forty-eight hours prior to the main experiments, we induced 
diabetes in healthy pigs by destroying their pancreatic beta cells using the 
cytotoxic agent streptozotocin 200 mg/kg i.v. (Zanosar, Teva Parenteral 
Medicines, Irvine, CA, USA) (21)(22). On the day of the experiment the 
animals were put under general anesthesia, an arterial line was established 
for monitoring and blood samples, central venous access was obtained, and 
the animals were instrumented with two IvS-1 sensors, one in each femoral 
artery. Animal handling, anesthesia and surgical intervention have been 
described in previous studies (4)(20).
 
 
IvS-1 calibration 
 ͳͳ
In order to achieve real-time continuous BGL output, the IvS-1 software had to 
be updated and a pre-insertion in vitro calibration procedure had to be 
determined. We applied a calibration procedure by exposing the sensor to 
buffer solutions with glucose concentrations of 0.0, 2.0 and 10.0 mmol/l. A 
nonlinear least square algorithm was used to compute the two calibration 
parameters describing the nonlinear calibration function. After insertion, the 
IvS-1-signal quickly stabilized. The time series from the IvS-1 was calibrated 
using the computed calibration parameters and a one-point calibration method 
to set the off-set parameter by adjusting the IvS-1 level with the blood glucose 
level achieved from a simultaneously drawn blood-sample analyzed on a bed-
side Radiometer ABL 720 blood-gas analyzer (Radiometer, Brønshøy, 
Denmark). Throughout the study several in vivo calibration procedures were 
performed to adjust for the inherent drift in the sensor. To ensure we had 
redundancy, we instrumented each animal with two IvS-1 sensors hard-wired 
to the same monitor. After the first in vivo calibration we chose whichever one 
had the most stable signal, and used data from this sensor for the rest of the 
experiment. 
 
Data handling, analyzes and statistics 
After the experiment, the IvS-1 data was retrieved by using data from the 
repetitive blood samples as calibration parameters. To transform the 
interferometric length measurement data into glucose concentration data, we 
used the nonlinear two-parameter calibration function described above. We 
compensated for baseline drift by using a fixed baseline drift rate, and 
compensated for pH interference by using the pH values from the blood-gas 
12
analyzer to compute pH corrected calibration parameters. The pH 
dependence of the calibration parameters was found from a set of in vitro 
experiments. 
 
  
 ͳ͵
RESULTS
 
This paper presents data from four animals, with the details shown in Figure 3 
and Table 1. The effect of the streptozotocin pre-treatment varied between 
animals; at the time of the first insulin bolus the starting BGL value (BGL0) 
ranged from 7.46 to 14.06 mmol/l. We were able to establish glycemic control 
by bringing the BGL below 6.0 mmol/l (Test) in 21 to 121 minutes, with the 
longest time in animals with a high BGL0 value. In animals 2-4, the rate of 
decrease (RD) from the first insulin bolus until the 6.0 mmol/l limit was 
reached was relatively high, from 0.064 – 0.077 (mmol/l)/min. (As a 
comparison, we found the maximum RD to be approximately 0.1 (mmol/l)/min 
after a single bolus dose of insulin in our earlier experiments (20).) After 
reaching the target range, the animals were kept under glycemic control (Tctrl) 
from 128 to 238 minutes. The total time with BGL values below the lower limit 
of the range, i.e. 4.5 mmol/l (Tlow), varied from 3 to 51 min in the four animals. 
The lowest BGL measured in the four animals (BGLlow) varied from 3.81 to 
4.44 mmol/l. 
 
(Figure 3 here) 
(Table 1 here) 
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DISCUSSION 
 
The intuitive interpretation of Figure 3 is that the fundamental principles of this 
AEP model work. BGL was rapidly and safely brought within the predefined 
range, and kept within the range during the study time. We tried to administer 
IB as best we could according to the algorithm; however, small details in the 
control algorithm had to be updated and changed as the experiments went on. 
We found that the animals behaved very differently in terms of their insulin 
needs. However, the time lag between IB and effect was predictable and in 
accordance with our previous research.  
 
The amplitude in BGL variations during established control was somewhat 
larger than desired. We believe the amplitude can be substantially decreased 
by further improvement in blood glucose sensor stability and improvement in 
the insulin regulatory algorithm. As explained in the introduction, actual 
pancreatic beta cells oscillate with a fixed time interval of approximately five 
minutes, whereas the amount of insulin released with each pulse is constantly 
changing. As the effect of a single IB starts to lower BGL in four to six 
minutes, and the nadir BGL values are reached after approximately 15 
minutes, consecutive insulin bursts from the pancreas with an interval of five 
minutes will yield a carryover effect where several bursts interfere with BGL at 
a given time. We found this regulation system to be too complicated to model 
at this stage, and therefore constructed a simplified system where the effect of 
each IB was followed throughout its effect period before a new IB was 
administered. In the future, a model able to correct for, and take advantage of, 
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this carryover effect might be constructed, either through the use of fixed 
interval IBs and/or IBs combined with a small continuous infusion of insulin.  
 
Current AEP models are based on subcutaneous glucose measurement and 
subcutaneous insulin administration. The insulin infusion algorithms are based 
on what is called model predictive control, where the pharmacokinetic 
properties of insulin are modeled in a series of equations that are used to 
calculate the correct insulin dose at a given time. Several studies have shown 
the feasibility of such systems in controlling BGL overnight in diabetic 
subjects. However, it is very challenging to calculate the correct insulin dose 
when the subject is eating, exercising or ill, and a fully automatic AEP thus 
has yet to be constructed (23)(24). We believe a more empirical system like 
ours could tackle such obstacles, as it allows for the correct insulin dose to be 
calculated and timed continuously based on the effect of the previous IB. In 
this system it is very unlikely that BGL would drift into hypoglycemic levels, or 
that it would rise into gross hyperglycemia. 
 
The main challenge during the study was that the IvS-1 was not optimally 
calibrated at all times, which led to small errors in the real-time BGL display. 
We therefore to some extent had to rely on a combination of the IvS-1 output 
and the blood samples to estimate the correct real-time BGL in order to use 
the insulin algorithm properly. The observed periods of BGL below the range’s 
lower limit were caused by a discrepancy between the observed real-time 
BGL and the correct BGL calculated after the experiment (the reported BGL). 
As such, the major limitation of the current technology is a background 
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swelling of the glucose-sensing hydrogel, which resulted in a drift in the IvS-1 
output. Our current work is focused on enhancing the hydrogel.  
 
There will always be some doubt as to whether results from animal studies 
are valid in a human population; on the other hand, the model makes it 
possible to manipulate BGL and to instrument study subjects without fear of 
any iatrogenic damage to healthy volunteers or patients. The IvS-1 probes 
used are all handcrafted and the set-up of the animal experiment is 
complicated, which is why the number of animals used in the study is low. 
However, all of the animals studied (both the final four as well as animals in 
our earlier studies) displayed the same behavior. The main point of this paper 
has been to illustrate the physiological principle of using nature’s own 
regulatory system in an artificial control system, without fine-tuning the details. 
 
 
 ͳ͹
CONCLUSIONS 
We conclude that the use of real-time accurate intravasal glucose monitoring 
in combination with repetitive bolus injections of insulin, administered to mimic 
the natural pulsatility of endogenous insulin, is a promising method for a future 
artificial pancreas. 
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FIGURES 
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Figure 1A: Pictures that show the hydrogel part of the IvS-1 continuous blood 
glucose monitor prototype at increasing magnification; B: a classic example of 
oscillating blood glucose levels with a periodicity of approximately 10 minutes 
and an amplitude of approximately 0.05 mmol/l (from animal 2, which was 
only mildly affected by the streptozotocin pretreatment; measurements from 
60 to 120 minutes in the actual experiment after IvS-1 stabilization but before 
the first insulin bolus; artifact seen at 103 minutes).  
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Figure 2: The current insulin algorithm; BGL: blood glucose level with the 
value in mmol/l; IB1-3: insulin bolus 1 to 3; BGC1-3 blood glucose control 1-3; 
ǻBGL the total amplitude in blood glucose level between two consecutive 
insulin boluses. 
 ʹ͵
 
 
Figure 3: Blood glucose control in four animals; the curves depict the blood 
glucose level, the histograms depict the insulin boluses and the horizontal 
dashed lines depict the ideal blood glucose target interval of 4.5 to 6.0 mmol/l. 
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TABLES 
Animal BGL0 
(mmol/l) 
BGLlow 
(mmol/l) 
Test 
(min) 
RD 
((mmol/l)/min) 
Tctrl 
(min) 
Tlow 
(min) 
Trange 
(%) 
1 7.53 3.81 68 0.025 186 51 73 
2 7.46 4.14 21 0.073 146 20 86 
3 9.33 4.44 63 0.064 238 3 99 
4 14.06 4.04 121 0.077 128 22 83 
 
 
Table 1: The seven outcome variables from the four animals; BGL0: the blood 
glucose level at the time of the first insulin bolus; BGLlow: the lowest blood 
glucose level recording during the experiment; Test: time to establish glycemic 
control from the first insulin bolus until the blood glucose level went below 6.0 
mmol/l; RD: the rate of blood glucose level decrease during Test; Tctrl: time with 
glycemic control from blood glucose level went below 6.0 mmol/l until end of 
experiment; Tlow: total time with blood glucose levels below 4.5 mmol/l during 
Tctrl; Trange: percentage time with BGL in the correct range between 4.5 and 
6.0 mmol/l during Tctrl 
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